Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Novel antimicrobial-resistant bacteria among patients requiring chronic hemodialysis.
Snyder GM, D'Agata EM.
Curr Opin Nephrol Hypertens. 2012 Mar;21(2):211-5.
Related citations
Sympathetic nervous system: role in hypertension and in chronic kidney disease.
Grassi G, Bertoli S, Seravalle G.
Curr Opin Nephrol Hypertens. 2012 Jan;21(1):46-51. Review.
Predictive modeling for improved anemia management in dialysis patients.
Brier ME, Gaweda AE.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):573-6. Review.
Should the knowledge gained from the Frequent Hemodialysis Network (FHN) trials change dialysis practice?
Levin NW, Raimann JG, Rocco MV.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):577-82. Review.
Creatinine-based formulae for estimating glomerular filtration rate: is it time to change to chronic kidney disease epidemiology collaboration equation?
Madero M, Sarnak MJ.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):622-30. Review.
Measurement of insulin resistance in chronic kidney disease.
Pham H, Utzschneider KM, de Boer IH.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):640-6. Review.
Urinary proteomics in the assessment of chronic kidney disease.
Mullen W, Delles C, Mischak H; EuroKUP COST action.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):654-61. Review.
Inflammation as a risk factor and target for therapy in chronic kidney disease.
Miyamoto T, Carrero JJ, Stenvinkel P.
Curr Opin Nephrol Hypertens. 2011 Nov;20(6):662-8. Review.
Polypharmacy and medication-related complications in the chronic kidney disease patient.
Mason NA.
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):492-7. Review.
Erythropoiesis-stimulating agents, hypertension and left ventricular hypertrophy in the chronic kidney disease patient.
Schmid H, Schiffl H, Lederer SR.
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):465-70. Review.
Optimal vitamin D, calcitriol, and vitamin D analog replacement in chronic kidney disease: to D or not to D: that is the question.
Moorthi RN, Kandula P, Moe SM.
Curr Opin Nephrol Hypertens. 2011 Jul;20(4):354-9. Review.
Use of estimated glomerular filtration rate for drug dosing in the chronic kidney disease patient.
Hudson JQ, Nyman HA.
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):482-91. Review.
Role of collaborative care models including pharmacists in improving blood pressure management in chronic kidney disease patients.
St Peter WL, Farley TM, Carter BL.
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):498-503. Review.
Aging and antihypertensive medication-related complications in the chronic kidney disease patient.
Marcum ZA, Fried LF.
Curr Opin Nephrol Hypertens. 2011 Sep;20(5):449-56. Review.
Calcium supplementation: lessons from the general population for chronic kidney disease and back.
Elder GJ.
Curr Opin Nephrol Hypertens. 2011 Jul;20(4):369-75. Review.
Extracellular matrix calcification in chronic kidney disease.
Toussaint ND.
Curr Opin Nephrol Hypertens. 2011 Jul;20(4):360-8. Review.
Therapeutic interventions for chronic kidney disease-mineral and bone disorders: focus on mortality.
Block GA.
Curr Opin Nephrol Hypertens. 2011 Jul;20(4):376-81. Review.
Has the incidence of end-stage renal disease in the USA and other countries stabilized?
Eggers PW.
Curr Opin Nephrol Hypertens. 2011 May;20(3):241-5.
Dysregulated mineral metabolism in children with chronic kidney disease.
Shroff R.
Curr Opin Nephrol Hypertens. 2011 May;20(3):233-40. Review.
Blood pressure goal in chronic kidney disease: what is the evidence?
Agarwal R.
Curr Opin Nephrol Hypertens. 2011 May;20(3):229-32. Review.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on